SecBot SecBot

ESPR

Esperion Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001434868 Biotech & Drug Discovery
No price
Market cap
$819.5M
Small cap
Median target
$3.16
range $3.16–3.28
Short interest
17.40M
≈6.8% of shares · −16.0%
Days to cover
1.7
at average volume
Insider net
−$342.7K
0 buyers · 3 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 9 exits
Filing reports
17
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 1 bullish oldest → newest, height = score
Avg score ·High conf. 2/2

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $342.7K.

  • InstitutionsBEARISH

    Q3 2026: 0 added (0 new), 9 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.007 → −$0.070 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersCOVERING

    Short interest −16.0% to 17.40M shares. 1.7 days to cover, ≈6.8% of shares.

Who's buying

13F· Q3 2026
0
new positions
9
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCEXIT0$0.00
FMR LLCEXIT0$0.00
UBS Group AGEXIT0$0.00
STATE STREET CORPEXIT0$0.00
VANGUARD CAPITAL MANAGEMENT LLCEXIT0$0.00
BlackRock, Inc.EXIT0$0.00
GOLDMAN SACHS GROUP INCDOUBLED10,380,646$32.8M
BALYASNY ASSET MANAGEMENT L.P.NEW4,654,778$14.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action May 2026
Recent actions
DateFirmActionRating
May 4, 2026Needham
DOWNGRADE
DOWNGRADEHold
May 1, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Mar 13, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Mar 3, 2026Needham
MAINTAIN
MAINTAINBuy
Nov 25, 2025Piper Sandler
INITIATE
INITIATEOverweight
Sep 19, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$342.7K
sold · 3 insiders
DateInsiderTypeValue
Jul 13, 2026
Koenig Sheldon L.
President and CEO
Jul 13, 2026
TO ISSUER647,460 sh
Jul 13, 2026
Halladay Benjamin
Chief Financial Officer
Jul 13, 2026
TO ISSUER200,000 sh
Jul 13, 2026
Hoffman Robert E.
Director
Jul 13, 2026
TO ISSUER85,153 sh
Jul 13, 2026
Hoffman Robert E.
Director
Jul 13, 2026
TO ISSUER40,000 sh
Jul 13, 2026
Hoffman Robert E.
Director
Jul 13, 2026
TO ISSUER7,040 sh
Jul 13, 2026
CARROLL J MARTIN
Director
Jul 13, 2026
TO ISSUER177,523 sh
Jul 13, 2026
CARROLL J MARTIN
Director
Jul 13, 2026
TO ISSUER21,000 sh
Jul 13, 2026
Looker Benjamin
Chief Legal Officer
Jul 13, 2026
TO ISSUER667,524 sh

Earnings setup

Estimates
−$0.07
EPS estimate, this quarter
−949%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Next FY$0.26$0.09–$0.49-11.8%$439.0M
Current Q-$0.07-$0.07–-$0.07+0.0%$76.6M
Next Q-$0.04-$0.04–-$0.04+0.0%$85.5M
Current FY-$0.21-$0.21–-$0.21+0.0%$337.6M

Short side

FINRA· Jun 30, 2026
17,401,689
shares short
-16.0%
vs prior settlement
1.7
days to cover
≈6.8%
of shares outstanding
Trading halts
Jul 10, 2026DeletionResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 SEC
Goldman Sachs Group Inc. filed an amendment to its Schedule 13G for Esperion Therapeutics, reporting a zero stake as…
SC 13G/A · Impact 4/10
Nov 10, 2026 Other
Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
ANN ARBOR, Mich., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Esperion, a company wholly-owned by ARCHIMED, to
Sep 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · EXIT
0 shares ($0.00)
Sep 30, 2026 Inst.
FMR LLC · EXIT
0 shares ($0.00)
Sep 3, 2026 SEC
Esperion Therapeutics won a favorable claim construction ruling in the Nexletol/Nexlizet ANDA litigation. The court…
COURT-RULING · Impact 5/10
Sep 3, 2026 Event
ESPERION THERAPEUTICS, INC. v. MICRO LABS USA, INC. et al
Court ruling (njd), Docket: 2:24-cv-05921
Aug 13, 2026 SEC
Esperion Therapeutics (ESPR) saw a mixed institutional cluster in 2026-Q2: 6 buyers (net +$5.0M) led by JPMorgan…
INST-CLUSTER · Impact 5/10
Jul 13, 2026 Insider
Koenig Sheldon L. disposed of 647,460 shares
President and CEO
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent
Nov 10, 2026
Press release
Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
ANN ARBOR, Mich., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a…
Nov 4, 2026
Earnings date
ESPR Q3 2026 Earnings Scheduled · 2026-11-04
Sep 3, 2026
Enforcement
ESPERION THERAPEUTICS, INC. v. MICRO LABS USA, INC. et al
Court ruling (njd), Docket: 2:24-cv-05921
Aug 3, 2026
Earnings date
ESPR Q2 2026 Earnings Scheduled, 2026-08-03
Jul 17, 2026
Clinical Trial
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Phase 2 · COMPLETED

SecBot reports

17 filings · 4 press releases · 8 bullish · 4 bearish · 1 mixed · 4 neutral
All ESPR filing & press-release reports (21)